Literature DB >> 22195126

A surveillance tool to support quality assurance and research in personalized medicine.

Naqi A Khan1, Josh F Peterson.   

Abstract

Developing effective methods to enable the practice of personalized medicine is a national priority for translational science. By leveraging modern genotyping technology and health information technologies, prescribing therapies based on genotype becomes an achievable goal. Within this manuscript, we describe the development, implementation, and piloting of a surveillance tool to assure the quality of clinical decision making in the context of new pharmacogenetic information. The surveillance tool allows a quality assurance (QA) team to review significant genotyping results and deliver focused educational interventions to providers. We report on the first eight patients undergoing genotyping to support antiplatelet therapy selection after drug-eluting stent placement. The collected pilot data supports an informatics approach to QA process management, as our tool delivered actionable patient information. It also enabled providers to tailor antiplatelet therapy to individual patients' genotypes. Our expectation is to continue collecting surveillance reports to perform an in-depth analysis of our tool.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22195126      PMCID: PMC3243202     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  34 in total

1.  Verifying quality and safety in health informatics services.

Authors:  M Rigby; J Forsström; R Roberts; J Wyatt
Journal:  BMJ       Date:  2001-09-08

2.  Biomedical informatics: changing what physicians need to know and how they learn.

Authors:  William W Stead; John R Searle; Henry E Fessler; Jack W Smith; Edward H Shortliffe
Journal:  Acad Med       Date:  2011-04       Impact factor: 6.893

3.  The path to personalized medicine.

Authors:  Margaret A Hamburg; Francis S Collins
Journal:  N Engl J Med       Date:  2010-06-15       Impact factor: 91.245

4.  Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.

Authors:  Guillaume Paré; Shamir R Mehta; Salim Yusuf; Sonia S Anand; Stuart J Connolly; Jack Hirsh; Katy Simonsen; Deepak L Bhatt; Keith A A Fox; John W Eikelboom
Journal:  N Engl J Med       Date:  2010-08-29       Impact factor: 91.245

5.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Authors:  Jessica L Mega; Tabassome Simon; Jean-Philippe Collet; Jeffrey L Anderson; Elliott M Antman; Kevin Bliden; Christopher P Cannon; Nicolas Danchin; Betti Giusti; Paul Gurbel; Benjamin D Horne; Jean-Sebastian Hulot; Adnan Kastrati; Gilles Montalescot; Franz-Josef Neumann; Lei Shen; Dirk Sibbing; P Gabriel Steg; Dietmar Trenk; Stephen D Wiviott; Marc S Sabatine
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

6.  Toward reuse of clinical data for research and quality improvement: the end of the beginning?

Authors:  Mark G Weiner; Peter J Embi
Journal:  Ann Intern Med       Date:  2009-07-28       Impact factor: 25.391

Review 7.  Predictive, personalized, preventive, participatory (P4) cancer medicine.

Authors:  Leroy Hood; Stephen H Friend
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

Review 8.  Biomedical informatics and translational medicine.

Authors:  Indra Neil Sarkar
Journal:  J Transl Med       Date:  2010-02-26       Impact factor: 5.531

9.  Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.

Authors:  Jacqueline Saw; Steven R Steinhubl; Peter B Berger; Dean J Kereiakes; Victor L Serebruany; Danielle Brennan; Eric J Topol
Journal:  Circulation       Date:  2003-08-18       Impact factor: 29.690

Review 10.  Comparative effectiveness research and genomic medicine: an evolving partnership for 21st century medicine.

Authors:  Muin J Khoury; Eugene C Rich; Gurvaneet Randhawa; Steven M Teutsch; John Niederhuber
Journal:  Genet Med       Date:  2009-10       Impact factor: 8.822

View more
  5 in total

1.  Pharmacotherapy in Older Adults with Cardiovascular Disease: Report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging Workshop.

Authors:  Janice B Schwartz; Kenneth E Schmader; Joseph T Hanlon; Darrell R Abernethy; Shelly Gray; Jacqueline Dunbar-Jacob; Holly M Holmes; Michael D Murray; Robert Roberts; Michael Joyner; Josh Peterson; David Lindeman; Ming Tai-Seale; Laura Downey; Michael W Rich
Journal:  J Am Geriatr Soc       Date:  2018-12-07       Impact factor: 5.562

2.  Physician response to implementation of genotype-tailored antiplatelet therapy.

Authors:  J F Peterson; J R Field; K M Unertl; J S Schildcrout; D C Johnson; Y Shi; I Danciu; J H Cleator; J M Pulley; J A McPherson; J C Denny; M Laposata; D M Roden; K B Johnson
Journal:  Clin Pharmacol Ther       Date:  2016-02-17       Impact factor: 6.875

3.  The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.

Authors:  J A Luzum; R E Pakyz; A R Elsey; C E Haidar; J F Peterson; M Whirl-Carrillo; S K Handelman; K Palmer; J M Pulley; M Beller; J S Schildcrout; J R Field; K W Weitzel; R M Cooper-DeHoff; L H Cavallari; P H O'Donnell; R B Altman; N Pereira; M J Ratain; D M Roden; P J Embi; W Sadee; T E Klein; J A Johnson; M V Relling; L Wang; R M Weinshilboum; A R Shuldiner; R R Freimuth
Journal:  Clin Pharmacol Ther       Date:  2017-06-09       Impact factor: 6.875

4.  Other side of the coin for personalised medicine and healthcare: content analysis of 'personalised' practices in the literature.

Authors:  Tomris Cesuroglu; Elena Syurina; Frans Feron; Anja Krumeich
Journal:  BMJ Open       Date:  2016-07-13       Impact factor: 2.692

5.  Attitudes of clinicians following large-scale pharmacogenomics implementation.

Authors:  J F Peterson; J R Field; Y Shi; J S Schildcrout; J C Denny; T L McGregor; S L Van Driest; J M Pulley; I M Lubin; M Laposata; D M Roden; E W Clayton
Journal:  Pharmacogenomics J       Date:  2015-08-11       Impact factor: 3.550

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.